Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 15/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiaramide SCHEMBL25172 | 0.90 | NPY5R (0.58) | NPY5RGAATSHRNPSR1TMEM97 | |
| Tiaramide SCHEMBL29376518 | 0.90 | NPY5R (0.58) | NPY5RGAATSHRNPSR1TMEM97 | |
| Tiaramide SCHEMBL181916 | 0.89 | NPY5R (0.58) | NPY5RGAATSHRNPSR1TMEM97 | |
| Tiaramide SCHEMBL29379184 | 0.89 | NPY5R (0.58) | NPY5RGAATSHRNPSR1TMEM97 | |
| SCHEMBL8894950 | 0.88 | TMEM97 (0.58) | NPY5RGAATSHRNPSR1TMEM97 | |
| SCHEMBL8902235 | 0.87 | NPY5R (0.56) | NPY5RGAATSHRNPSR1TMEM97 | |
| SCHEMBL11408981 | 0.85 | NPY5R (0.57) | NPY5RGAATSHRNPSR1TMEM97 | |
| SCHEMBL10546335 | 0.84 | NPY5R (0.59) | NPY5RGAATSHRNPSR1TDP1 | |
| SCHEMBL10544707 | 0.84 | NPY5R (0.59) | NPY5RGAATSHRNPSR1TMEM97 | |
| SCHEMBL10547671 | 0.84 | NPY5R (0.61) | NPY5RGAATSHRNPSR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239916-A1 | NOVEL DRUG DISCOVERY TARGET AND MEDICINE ACTING ON THE SAME | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239916-A1 | NOVEL DRUG DISCOVERY TARGET AND MEDICINE ACTING ON THE SAME | LCP2, FPR2, MFN2 | NPY5R 4169/4885GAA 2054/4885TSHR 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.